Nasus Pharma Ltd. (NSRX) Financials

Nasus Pharma Ltd. (NSRX) recorded an outflow of $4.9M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Nasus Pharma Ltd. (NSRX) recorded an outflow of $4.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Nasus Pharma Ltd. (NSRX) had $5.0M in total assets as of fiscal year 2025, including both current and long-term assets.

Nasus Pharma Ltd. (NSRX) invested $14K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Nasus Pharma Ltd. (NSRX) invested $2.2M in research and development during fiscal year 2025.

Nasus Pharma Ltd. (NSRX) had 9M shares outstanding as of fiscal year 2025.

Nasus Pharma Ltd. (NSRX) had a current ratio of 2.24 as of fiscal year 2025, which is generally considered healthy.

Nasus Pharma Ltd. (NSRX) had a liabilities-to-equity ratio of 0.81 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Nasus Pharma Ltd. (NSRX) had a return on assets of -117.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Nasus Pharma Ltd. (NSRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $36.0M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Nasus Pharma Ltd. (NSRX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $36.0M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Nasus Pharma Ltd. (NSRX) held $1.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.9M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Nasus Pharma Ltd. (NSRX) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Nasus Pharma Ltd. (NSRX) reported a net loss of $5.9M while operations used $4.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Nasus Pharma Ltd. (NSRX) reported an operating loss of $4.9M against $78K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.